Glioblastoma is the most common and aggressive brain tumor in adults. Despite surgery, radiation, and chemotherapy, survival rates remain low, which emphasizes the urgent need for improved therapies. Current preclinical models use untreated tumors, which do not reflect the clinical scenario where patients already receive initial treatments. This review examines the effects of current treatments on the properties of recurrent tumors and evaluates preclinical models that incorporate these standard treatments to better mimic real patient conditions. Improving these models could help to identify more effective treatments, potentially leading to better outcomes for glioblastoma patients.
Hady presents at the Trainee Research Day
Hady presented a poster on anti-amyloid antibodies and their effects on blood-brain barrier integrity at the College of Medicine Trainee Research Day. This work represents a new and timely research direction in the lab that aligns with the development of novel disease-modifying antibody therapeutics for Alzheimer’s disease.
March 23, 2026
